218 related articles for article (PubMed ID: 22715394)
1. Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.
Takata Y; Kristal AR; Santella RM; King IB; Duggan DJ; Lampe JW; Rayman MP; Blount PL; Reid BJ; Vaughan TL; Peters U
PLoS One; 2012; 7(6):e38612. PubMed ID: 22715394
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans.
Takata Y; King IB; Lampe JW; Burk RF; Hill KE; Santella RM; Kristal AR; Duggan DJ; Vaughan TL; Peters U
J Nutr; 2012 Mar; 142(3):419-26. PubMed ID: 22259188
[TBL] [Abstract][Full Text] [Related]
3. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
Dong LM; Kristal AR; Peters U; Schenk JM; Sanchez CA; Rabinovitch PS; Blount PL; Odze RD; Ayub K; Reid BJ; Vaughan TL
Nutr Cancer; 2008; 60(1):39-48. PubMed ID: 18444134
[TBL] [Abstract][Full Text] [Related]
4. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
5. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
6. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus.
Siahpush SH; Vaughan TL; Lampe JN; Freeman R; Lewis S; Odze RD; Blount PL; Ayub K; Rabinovitch PS; Reid BJ; Chen C
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2387-95. PubMed ID: 18006928
[TBL] [Abstract][Full Text] [Related]
8. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
[TBL] [Abstract][Full Text] [Related]
9. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
10. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma.
Peters U; Chatterjee N; Hayes RB; Schoen RE; Wang Y; Chanock SJ; Foster CB
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1144-54. PubMed ID: 18483336
[TBL] [Abstract][Full Text] [Related]
11. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
12. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer.
Geybels MS; van den Brandt PA; Schouten LJ; van Schooten FJ; van Breda SG; Rayman MP; Green FR; Verhage BA
J Natl Cancer Inst; 2014 Mar; 106(3):dju003. PubMed ID: 24563517
[TBL] [Abstract][Full Text] [Related]
13. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.
Peng S; Huo X; Rezaei D; Zhang Q; Zhang X; Yu C; Asanuma K; Cheng E; Pham TH; Wang DH; Chen M; Souza RF; Spechler SJ
Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G129-39. PubMed ID: 24852569
[TBL] [Abstract][Full Text] [Related]
14. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
15. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.
Duggan C; Onstad L; Hardikar S; Blount PL; Reid BJ; Vaughan TL
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):934-43. PubMed ID: 23466711
[TBL] [Abstract][Full Text] [Related]
16. Impact of Glutathione Peroxidase-1 (Gpx1) Genotype on Selenoenzyme and Transcript Expression When Repleting Selenium-Deficient Mice.
Sunde RA; Zemaitis ET; Blink AB; Lawinger JA
Biol Trace Elem Res; 2018 Nov; 186(1):174-184. PubMed ID: 29502249
[TBL] [Abstract][Full Text] [Related]
17. Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1.
Jablonska E; Gromadzinska J; Peplonska B; Fendler W; Reszka E; Krol MB; Wieczorek E; Bukowska A; Gresner P; Galicki M; Zambrano Quispe O; Morawiec Z; Wasowicz W
BMC Cancer; 2015 Oct; 15():657. PubMed ID: 26446998
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett's Esophagus Compared to Esophageal Adenocarcinoma.
O'Farrell NJ; Phelan JJ; Feighery R; Doyle B; Picardo SL; Ravi N; O'Toole D; Reynolds JV; O'Sullivan J
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509954
[TBL] [Abstract][Full Text] [Related]
19. Influence of the glutathione peroxidase 1 Pro200Leu polymorphism on the response of glutathione peroxidase activity to selenium supplementation: a randomized controlled trial.
Miller JC; Thomson CD; Williams SM; van Havre N; Wilkins GT; Morison IM; Ludgate JL; Skeaff CM
Am J Clin Nutr; 2012 Oct; 96(4):923-31. PubMed ID: 22952184
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W
Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
